| dc.relation.references | 1. ŠVEC, P.; FRANZ, C. M. A. P. The Genus Enterococcus. In: HOLZAPFEL, W. H.;
WOOD, B. J. (Eds.). Lactic Acid Bacteria: Biodiversity and Taxonomy. UK: John
Wiley & Sons Ltd, 2014. p. 175–211.
2. MUNDT, J. O. Occurrence of Enterococci in Animals in a Wild Environment. Applied
Microbiology, Basel, v. 11, n. 2, p. 136–140, 1963.
3. MARTIN, J. D.; MUNDT, J. O. Enterococci in Insects. Applied Microbiology, Basel, v.
24, n. 4, p. 575–580, 1972.
4. MOON, B.-Y. et al. Antimicrobial Resistance Profiles of Enterococcus faecium and
Enterococcus faecalis Isolated from Healthy Dogs and Cats in South Korea.
Microorganisms, Basel, v. 11, n. 12, p. 2991, 2023.
5. TEIXEIRA, L. M. et al. Enterococcus. In: JORGENSEN, J. H. et al. (Eds.). Manual of
Clinical Microbiology. Washington, DC: ASM Press, 2015. p. 403–421.
6. DAUTLE, M. P.; WILKINSON, T. ROSS.; GAUDERER, M. W. L. Isolation and
identification of biofilm microorganisms from silicone gastrostomy devices. Journal of
Pediatric Surgery, United States, v. 38, n. 2, p. 216–220, 2003. DOI:
10.1053/jpsu.2003.50046.
7. HASHEM, Y. A. et al. Biofilm formation in enterococci: genotype-phenotype correlations
and inhibition by vancomycin. Scientific Reports, London, v. 7, n. 1, 2017.
8. GUARDABASSI, L. Pet animals as reservoirs of antimicrobial-resistant bacteria: Review.
Journal of Antimicrobial Chemotherapy, London, v. 54, n. 2, p. 321–332, 1 jul. 2004.
DOI: 10.1093/jac/dkh332.
9. DAHL, A. et al. Prevalence of Infective Endocarditis in Enterococcus faecalis Bacteremia.
Journal of the American College of Cardiology, United States, v. 74, n. 2, p. 193–201,
2019.
10. SAID, M. S.; TIRTHANI, E.; LESHO, E. Enterococcus Infections [Internet].2024 [acesso
em: 2025 nov 15]. Disponível em: https://www.ncbi.nlm.nih.gov/books/NBK567759/.
11. ZHEN, X. et al. Economic burden of antibiotic resistance in ESKAPE organisms: a
systematic review. Antimicrobial Resistance & Infection Control, London, v. 8, n. 1,
2019. DOI: 10.1186/s13756-019-0590-7.
12. TAPPEINER, H.; JESIONEK, A. Therapeutische Versuche mit fluoreszierenden Stoffen.
Münch Med Wochenschr, Germany, v. 47, n. 1, p. 2042–2044, 1903.
13. HAMBLIN, M. R. Antimicrobial photodynamic inactivation: a bright new technique to kill
resistant microbes. Current Opinion in Microbiology, London, v. 33, p. 67–73, 1 out.
2016.
14. DAI, T.; HUANG, Y.-Y.; HAMBLIN, M. R. Photodynamic therapy for localized
infections—State of the art. Photodiagnosis and Photodynamic Therapy, Netherlands, v.
6, n. 3-4, p. 170–188, 2009.
15. GUTERRES, K. B. et al. Preliminary evaluation of the positively and negatively charge
effects of tetra-substituted porphyrins on photoinactivation of rapidly growing
66
mycobacteria. Tuberculosis, [s.l], v. 117, p. 45–51, 2019. DOI:
10.1016/j.tube.2019.06.001.
16. LEHNINGER, A. L.; NELSON, D. L.; COX, M. M. Lehninger Principles of
Biochemistry. 8. ed. New York, US: W.H. Freeman, 2005.
17. NERIS, R. L. S. et al. Co-protoporphyrin IX and Sn-protoporphyrin IX inactivate Zika,
Chikungunya and other arboviruses by targeting the viral envelope. Scientific Reports,
London, v. 8, n. 1, p. 9805, 2018.
18. HOLOUBEK, J. et al. Antiviral activity of porphyrins and porphyrin-like compounds
against tick-borne encephalitis virus: Blockage of the viral entry/fusion machinery by
photosensitization-mediated destruction of the viral envelope. Antiviral Research, [s.l], v.
221, p. 105767, 2024. DOI: https://doi.org/10.1016/j.antiviral.2023.105767.
19. FABRIS, C. et al. Effects of a new photoactivatable cationic porphyrin on ciliated protozoa
and branchiopod crustaceans, potential components of freshwater ecosystems polluted by
pathogenic agents and their vectors. Photochemical & Photobiological Sciences., [s.l], v.
11, n. 2, p. 294–301, 2012.
20. ABADA, Z. et al. Synthesis and antiprotozoal activity of original porphyrin precursors and
derivatives. European Journal of Medicinal Chemistry, [s.l], v. 67, p. 158–165, 2013.
DOI: https://doi.org/10.1016/j.ejmech.2013.06.002.
21. MOGHNIE, S. et al. Cationic amphiphilic Zn-porphyrin with high antifungal
photodynamic potency. Photochemical & Photobiological Sciences, [s.l.], v. 16, n. 11, p.
1709–1716, 2017.
22. SOUZA, S. O. et al. Photoinactivation of Yeast and Biofilm Communities of Candida
albicans Mediated by ZnTnHex-2-PyP4+ Porphyrin. Journal of Fungi, Basel, v. 8, n. 6, p.
556, 25 maio 2022.
23. AMORIM, C. F. et al. Photodynamic inactivation of different Candida species and
inhibition of biofilm formation induced by water-soluble porphyrins. Photodiagnosis and
photodynamic therapy, Netherlands, v. 42, p. 103343, 1 jun. 2023. DOI:
10.1016/j.pdpdt.2023.103343.
24. TASLI, H. et al. Photodynamic antimicrobial activity of new porphyrin derivatives against
methicillin resistant Staphylococcus aureus. Journal of Microbiology, [s.l], v. 56, n. 11, p.
828–837, 24 out. 2018.
25. WANG, J. et al. Visible light-induced biocidal activities and mechanistic study of neutral
porphyrin derivatives against S. aureus and E. coli. Journal of Photochemistry and
Photobiology B: Biology, Netherlands, v. 185, p. 199–205, 2018. DOI:
https://doi.org/10.1016/j.jphotobiol.2018.06.003
26. SILVEIRA, C. H. DA et al. Investigation of isomeric tetra-cationic porphyrin activity with
peripheral [Pd(bpy)Cl]+ units by antimicrobial photodynamic therapy. Photodiagnosis
and Photodynamic Therapy, Netherlands, v. 31, p. 101920, 2020. DOI:
https://doi.org/10.1016/j.pdpdt.2020.101920.
27. URQUHART, C. G. et al. Antimicrobial activity of water-soluble tetra-cationic porphyrins
on Pseudomonas aeruginosa. Photodiagnosis Photodyn Ther., Netherlands, v. 42, p.
103266–103266, jun. 2023.
67
28. SEEGER, M. G. et al. Antibiofilm action using water-soluble tetra-cationic porphyrin and
antibacterial photodynamic therapy against Moraxella spp. from cattle. Microbial
Pathogenesis, United States, v. 178, p. 106081–106081, maio 2023.
29. BONDI, M. et al. Inhibition of Multidrug-Resistant Gram-Positive and Gram-Negative
Bacteria by a Photoactivated Porphyrin. Polish Journal of Microbiology, Poland, v. 66, n.
4, p. 533–536, 1 jan. 2017.
30. PINHEIRO, T. DA R. et al. Antimicrobial photodynamic in vitro inactivation of
Enterococcus spp. and Staphylococcus spp. strains using tetra-cationic platinum(II)
porphyrins. Photodiagnosis and Photodynamic Therapy, Netherlands, v. 42, p. 103542,
2023.
31. DIOGO, P. et al. Antimicrobial Photodynamic Therapy against Endodontic Enterococcus
faecalis and Candida albicans Mono and Mixed Biofilms in the Presence of
Photosensitizers: A Comparative Study with Classical Endodontic Irrigants. Frontiers in
Microbiology, Switzerland, v. 8, 30 mar. 2017.
32. RAVANAT, J.-L. et al. Singlet Oxygen Induces Oxidation of Cellular DNA. Journal of
Biological Chemistry, [s.l], v. 275, n. 51, p. 40601–40604, dez. 2000.
33. STARK, G. Functional Consequences of Oxidative Membrane Damage. Journal of
Membrane Biology, United States, v. 205, n. 1, p. 1–16, 2005.
34. SAVELYEVA, I. O. et al. Cationic Porphyrins as Antimicrobial and Antiviral Agents in
Photodynamic Therapy. Current Issues in Molecular Biology, Switzerland, v. 45, n. 12,
p. 9793–9822, 6 dez. 2023.
35. WAINWRIGHT, M.; CROSSLEY, K. B. Photosensitising agents—circumventing
resistance and breaking down biofilms: a review. International Biodeterioration &
Biodegradation, England, v. 53, n. 2, p. 119–126, 2004.
36. THIERCELIN, M. E. Morphologie et modes de reproduction de l’enterocoque. Comptes
Rendus des Seances de la Societe de Biologie et des ses Filiales, France, v. 11, n. 11, p.
551–553, 1899.
37. THIERCELIN, M. E.; JOUHAUD, L. Sur un diplocoque saprophyte de l’intestin
susceptible de devenir pathogene. CR Soc Biol, France, v. 5, 1899.
38. LANCEFIELD, R. C. A serological differentiation of human and other groups of hemolytic
streptococci. Journal of Experimental Medicine, [s.l], v. 57, n. 4, p. 571–595, 1 abr.
1933. DOI: 10.1084/jem.57.4.571.
39. SCHLEIFER, K. H.; KILPPER-BALZ, R. Transfer of Streptococcus faecalis and
Streptococcus faecium to the Genus Enterococcus nom. rev. as Enterococcus faecalis
comb. nov. and Enterococcus faecium comb. nov. International Journal of Systematic
Bacteriology, England, v. 34, n. 1, p. 31–34, 1 jan. 1984.
40. SCHOCH, C. L. et al. NCBI Taxonomy: a comprehensive update on curation, resources
and tools. Database (Oxford), v. 2020, 2020.
41. FACKLAM, R. R. Comparison of Several Laboratory Media for Presumptive
Identification of Enterococci and Group D Streptococci. Applied Microbiology, England,
v. 26, n. 2, p. 138–145, 1973.
42. BRASIL. AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA (ANVISA).
Microbiologia Clínica para o Controle de Infecção Relacionada à Assistência à Saúde.
68
Módulo 6 : Detecção e identificação de bactérias de importância médica. Brasília, BR:
Anvisa, 2013.
43. ŠVEC, P.; DEVRIESE, L. A. Enterococcus. In: TRUJILLO, M. E. et al. (Eds.). Bergey’s
Manual of Systematics of Archaea and Bacteria. [s.l: s.n.]. p. 1–25.
44. ZHONG, Z. et al. Comparative genomic analysis of the genus Enterococcus.
Microbiological Research, Germany, v. 196, p. 95–105, 1 mar. 2017. DOI:
https://doi.org/10.1016/j.micres.2016.12.009.
45. GARCÍA-SOLACHE, M.; RICE, L. B. The Enterococcus: a Model of Adaptability to Its
Environment. Clinical Microbiology Reviews, United States, v. 32, n. 2, 20 mar. 2019.
46. BIZZINI, A.; GREUB, G. Matrix-assisted laser desorption ionization time-of-flight mass
spectrometry, a revolution in clinical microbial identification. Clinical Microbiology and
Infection, England, v. 16, n. 11, p. 1614–1619, 2010.
47. STĘPIEŃ–PYŚNIAK, D. et al. MALDI-TOF Mass Spectrometry as a Useful Tool for
Identification of Enterococcus spp. from Wild Birds and Differentiation of Closely Related
Species. Journal of Microbiology and Biotechnology, Korea, v. 27, n. 6, p. 1128–1137,
28 jun. 2017.
48. GRIFFIN, P. M. et al. Use of Matrix-Assisted Laser Desorption Ionization–Time of Flight
Mass Spectrometry To Identify Vancomycin-Resistant Enterococci and Investigate the
Epidemiology of an Outbreak. Journal of Clinical Microbiology,
United States, v. 50, n. 9, p. 2918–2931, 2012.
49. PARTE, A. C. et al. List of Prokaryotic names with Standing in Nomenclature (LPSN)
moves to the DSMZ. International Journal of Systematic and Evolutionary
Microbiology, England, v. 70, n. 11, p. 5607–5612, 1 nov. 2020.
50. SCHWARTZMAN, J. A. et al. Global diversity of enterococci and description of 18
previously unknown species. Proceedings of the National Academy of Sciences of the
United States of America, United States, v. 121, n. 10, 28 fev. 2024.
51. MUNDT, J. O.; JOHNSON, A. H.; KHATCHIKIAN, R. Incidence and nature of
enterococci on plant materials. Journal of Food Science, United States, v. 23, n. 2, p. 186–
193, 1958.
52. MUNDT, J. O. Occurrence of Enterococci: Bud, Blossom, and Soil Studies. Applied
Microbiology, Basel, v. 9, n. 6, p. 541–544, 1 nov. 1961.
53. MUNDT, J. O. Occurrence of Enterococci on Plants in a Wild Environment. Applied
Microbiology, Basel, v. 11, n. 2, p. 141–144, 1963.
54. ATOR, L. L.; STARZYK, M. J. Distribution of group D streptococci in rivers and streams.
PubMed, [s.l], v. 16, n. 64, p. 91–104, 1976.
55. GIRAFFA, G. Enterococci from foods. FEMS Microbiology Reviews, England, v. 26, n.
2, p. 163–171, 2002.
56. TORRE, I. et al. Antimicrobial susceptibility and glycopeptide-resistance of enterococci in
vegetables. Italian Journal of Public Health, Italy, v. 7, n. 1, 2010. DOI:10.2427/5746.
57. LEBRETON, F.; WILLEMS, R. J. L.; GILMORE, M. S. Enterococcus Diversity, Origins
in Nature, and Gut Colonization. In: GILMORE, M. S. et al. (Eds.). Enterococci: From
69
Commensals to Leading Causes of Drug Resistant Infection. Boston, US:
Massachusetts Eye and Ear Infirmary, 2014. p. 1-46.
58. CHAO, C.; YANG, S.; HUANG, J. Peritoneal Dialysis Peritonitis Caused by Enterococcus
avium. Peritoneal Dialysis International, Canadá, v. 33, n. 3, p. 335–336, 1 maio 2013.
59. POCHHAMMER, J.; KRAMER, A.; SCHÄFFER, M. Enterokokken Und Postoperative
Wundinfektionen. Der. Chirurg, [s.l.], v. 88, n. 5, p. 377–384, 2017.
60. ANTONELLO, V. S. et al. Enterococcus gallinarum meningitis in an immunocompetent
host: a case report. Revista do Instituto de Medicina Tropical de São Paulo, São Paulo,
v. 52, n. 2, p. 111–112, 1 abr. 2010. DOI: 10.1590/s0036-46652010000200009.
61. BUTLER, J. S. et al. Nontuberculous Pyogenic Spinal Infection in Adults:a 12-year
experience from a tertiary referral center. Spine, [s l], v. 31, n. 23, p. 2695–2700, nov.
2006. DOI: 10.1097/01.brs.0000244662.78725.37.
62. SUNDQVIST, G. et al. Microbiologic analysis of teeth with failed endodontic treatment
and the outcome of conservative re-treatment. Oral Surgery, Oral Medicine, Oral
Pathology, Oral Radiology, and Endodontology, United States, v. 85, n. 1, p. 86–93,
1998.
63. NNIS SYSTEM. National Nosocomial Infections Surveillance (NNIS) System Report,
Data Summary from January 1990-May 1999, Issued June 1999. A report from the NNIS
System. American Journal of Infection Control, Rio de Janeiro, v. 27, n. 6, p. 520–532,
1999. DOI: 10.1016/s0196-6553(99)70031-3.
64. HAMMERUM, A. M. Enterococci of animal origin and their significance for public health.
Clinical Microbiology and Infection, England, v. 18, n. 7, p. 619–625, jul. 2012.
65. JAHAN, M.; HOLLEY, R. A. Incidence of virulence factors in enterococci from raw and
fermented meat and biofilm forming capacity at 25°C and 37°C. International Journal of
Food Microbiology, Netherlands, v. 170, p. 65–69, 10 nov. 2013.
66. ZAIDI, S.-E.-Z. et al. Genomic Characterization of Enterococcus hirae From Beef Cattle
Feedlots and Associated Environmental Continuum. Frontiers in Microbiology,
Switzerland, v. 13, 27 jun. 2022. DOI: 10.3389/fmicb.2022.859990.
67. KAGKLI, D. M. et al. Enterococcus and Lactobacillus contamination of raw milk in a
farm dairy environment. International Journal of Food Microbiology, Netherlands, v.
114, n. 2, p. 243–251, mar. 2007.
68. CHIANG, H.-Y. et al. Incidence and Outcomes Associated With Infections Caused by
Vancomycin-Resistant Enterococci in the United States: Systematic Literature Review and
Meta-Analysis. Infection Control & Hospital Epidemiology, United States, v. 38, n. 2, p.
203–215, 9 nov. 2016. DOI: 10.1017/ice.2016.254.
69. SHERMAN, J. M. The Enterococci and Related Streptococci. Journal of Bacteriology,
United States, v. 35, n. 2, p. 81–93, fev. 1938.
70. MILLER, W. R. et al. Vancomycin-Resistant Enterococci. Infectious Disease Clinics of
North America, United States, v. 30, n. 2, p. 415–439, jun. 2016.
71. FIORE, E.; VAN TYNE, D.; GILMORE, M. S. Pathogenicity of Enterococci.
Microbiology Spectrum, United States, v. 7, n. 4, 5 jul. 2019.
70
72. REYES, K.; BARDOSSY, A. C.; ZERVOS, M. Vancomycin-Resistant Enterococci.
Infectious Disease Clinics of North America, United States, v. 30, n. 4, p. 953–965, dez.
2016.
73. ANTALEK, M. D. et al. Clinical and Molecular Epidemiology of Enterococcus faecalis
Bacteremia, with Special Reference to Strains with High-Level Resistance to Gentamicin.
Clinical Infectious Diseases, United States, v. 20, n. 1, p. 103–109, 1 jan. 1995.
74. BLASEG, N. A.; HOOVER, S. E. Wound Infection With Enterococcus hirae Associated
With Cat Litter. Infectious Diseases in Clinical Practice, United States, v. 29, n. 4, p.
e242–e243, jul. 2021. DOI:10.1097/IPC.0000000000000959.
75. PENG, C.-H. et al. Multiresistant enterococci: a rare cause of complicated corneal ulcer
and review of the literature. Canadian Journal of Ophthalmology, England, v. 44, n. 2, p.
214–215, 1 abr. 2009.
76. CHUNG, Y. S. et al. Characterization of Veterinary Hospital-Associated Isolates of
Enterococcus Species in Korea. Journal of Microbiology and Biotechnology, Korea, v.
24, n. 3, p. 386–393, 28 mar. 2014. DOI: 10.4014/jmb.1310.10088.
77. LESTER, C. H. et al. In Vivo Transfer of the vanA Resistance Gene from an Enterococcus
faecium Isolate of Animal Origin to an E. faecium Isolate of Human Origin in the Intestines
of Human Volunteers. Antimicrobial Agents and Chemotherapy, United States, v. 50, n.
2, p. 596–599, 25 jan. 2006. DOI: 10.1128/AAC.50.2.596-599.2006.
78. ARIAS, C. A.; MURRAY, B. E. The rise of the Enterococcus: beyond vancomycin
resistance. Nature reviews. Microbiology, England, v. 10, n. 4, p. 266–78, 2012.
79. GUZMAN PRIETO, A. M. et al. Global Emergence and Dissemination of Enterococci as
Nosocomial Pathogens: Attack of the Clones? Frontiers in Microbiology, Switzerland, v.
7, 26 maio 2016.
80. ODENSVIK, K.; GRAVE, K.; GREKO, C. Antibacterial Drugs Prescribed for Dogs and
Cats in Sweden and Norway 1990–1998. Acta Veterinaria Scandinavica, United
Kingdom, v. 42, n. 1, p. 189, 31 mar. 2001.
81. EVANS PATTERSON, J. et al. An Analysis of 110 Serious Enterococcal Infections
Epidemiology, Antibiotic Susceptibility, and Outcome. Medicine (Baltimore), v. 74, n. 4,
p. 191–200, jul. 1995. DOI: 10.1097/00005792-199507000-00003.
82. CHIRURGI, V. A. Nosocomial Acquisition of ß-Lactamase—Negative, AmpicillinResistant Enterococcus. Archives of Internal Medicine, United States, v. 152, n. 7, p.
1457, 1 jul. 1992.
83. NAUSCHUETZ, W. F. et al. Enterococcus casseliflavus as an agent of nosocomial
bloodstream infections. Medical Microbiology Letters, England, v. 2, n. 2, p. 102–108,
1993.
84. CANALEJO, E. et al. Bacteraemic spondylodiscitis caused by Enterococcus hirae.
European Journal of Clinical Microbiology & Infectious Diseases, Germany, v. 27, n.
7, p. 613–615, 28 fev. 2008. DOI: 10.1007/s10096-008-0476-8.
85. ANDREWES, F. W.; HORDER, T. J. A study of the streptococci pathogenic for man.
Lancet, London, v. 168, n. 4333, p. 708–713, set. 1906. DOI:
https://doi.org/10.1016/S0140-6736(01)31538-6
86. ORLA-JENSEN, S. The Lactic Acid Bacteria. Copenhagen: Host & Son, 1919. p. 1–118.
71
87. HIDRON, A. I. et al. Antimicrobial-Resistant Pathogens Associated With HealthcareAssociated Infections: Annual Summary of Data Reported to the National Healthcare
Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infection
Control & Hospital Epidemiology, United States, v. 29, n. 11, p. 996–1011, nov. 2008.
88. WEINER, L. M. et al. Antimicrobial-Resistant Pathogens Associated With HealthcareAssociated Infections: Summary of Data Reported to the National Healthcare Safety
Network at the Centers for Disease Control and Prevention, 2011–2014. Infection Control
& Hospital Epidemiology, United States, v. 37, n. 11, p. 1288–1301, 30 ago. 2016.
89. VAN HAUWERMEIREN, E. et al. Development of case vignettes for assessment of the
inter-rater variability of national validation teams for the point prevalence survey of
healthcare-associated infections and antimicrobial use in European acute care hospitals.
Journal of Hospital Infection, London, v. 101, n. 4, p. 455–460, abr. 2019.
90. TOP, J. et al. Ecological replacement of Enterococcus faecalis by multiresistant clonal
complex 17 Enterococcus faecium. Clinical Microbiology and Infection, England, v. 13,
n. 3, p. 316–319, mar. 2007. DOI: 10.1111/j.1469-0691.2006.01631.x.
91. ABAT, C. et al. Enterococcus faecalis urinary-tract infections: Do they have a zoonotic
origin? Journal of Infection, [s.l], v. 73, n. 4, p. 305–313, out. 2016.
92. MULLALLY, C. A. et al. Non-faecium non-faecalis enterococci: a review of clinical
manifestations, virulence factors, and antimicrobial resistance. Clinical microbiology
reviews, United States, v.37, n.2, p. e0012123, 11 mar. 2024. DOI: 10.1128/cmr.00121-23.
93. PERIO, M. A. et al. Risk Factors and Outcomes Associated With Non–Enterococcus
faecalis, Non–Enterococcus faecium Enterococcal Bacteremia. Infection Control &
Hospital Epidemiology, United States, v. 27, n. 1, p. 28–33, jan. 2006.
94. MASTROIANNI, A. Enterococcus raffinosus endocarditis. First case and literature review.
Le Infezioni in Medicina, Italy, v. 1, p. 14–20, 2009.
95. PINKES, M. E.; WHITE, C.; WONG, C. S. Native-valve Enterococcus hirae endocarditis:
a case report and review of the literature. BMC Infectious Diseases, England, v. 19, n. 1,
24 out. 2019.
96. ZHAO, B.; YE, M. S.; ZHENG, R. Enterococcus gallinarum meningitis: a case report and
literature review. BMC Infectious Diseases, England, v. 18, n. 1, 21 maio 2018.
97. AMARO, P. et al. Multifocal joint infection caused by Enterococcus gallinarum. Modern
Rheumatology Case Reports, England, v. 5, n. 2, p. 384–386, 6 nov. 2020.
98. TENG, T. Z. J.; SHELAT, V. G. Letter to the Editor: Enterococcus gallinarum Causing
Acute Cholangitis in an Immunocompetent Patient. Surgical Infections, United States, v.
23, n. 1, p. 93–94, 7 set. 2021.
99. VAUGHAN, D. H.; RIGGSBY, W. S.; MUNDT, J. O. Deoxyribonucleic Acid Relatedness
of Strains of Yellow-Pigmented, Group D Streptococci. International Journal of
Systematic Bacteriology, England, v. 29, n. 3, p. 204–212, 1 jul. 1979. DOI:
https://doi.org/10.1099/00207713-29-3-204
100. COLLINS, M. D. et al. Enterococcus avium nom. rev., comb. nov.; E. casseliflavus nom.
rev., comb. nov.; E. durans nom. rev., comb. nov.; E. gallinarum comb. nov.; and E.
malodoratus sp. nov. International Journal of Systematic Bacteriology, England, v. 34,
n. 2, p. 220–223, 1 abr. 1984.
72
101. GORDTS, B. et al. Vancomycin-resistant enterococci colonizing the intestinal tracts of
hospitalized patients. J. Clin. Microbiol., United States, v.33, n. 11, p. 2842–2846, 1 nov.
1995.
102. TOYE, B. et al. Clinical and epidemiological significance of enterococci intrinsically
resistant to vancomycin (possessing the vanC genotype). Journal of Clinical
Microbiology, United States, v. 35, n. 12, p. 3166–3170, 1 dez. 1997. DOI:
10.1128/jcm.35.12.3166-3170.1997.
103. VAN HORN, K. G.; RODNEY, K. M. Colonization and microbiology of the motile
enterococci in a patient population. Diagnostic Microbiology and Infectious Disease,
United States, v. 31, n. 4, p. 525–530, 1 ago. 1998. DOI: 10.1016/s0732-8893(98)00052-2.
104. CHOI, S. et al. Clinical Features and Outcomes of Bacteremia Caused by Enterococcus
casseliflavus and Enterococcus gallinarum: Analysis of 56 Cases. Clinical Infectious
Diseases, United States, v. 38, n. 1, p. 53–61, jan. 2004.
105. ABAMECHA, A.; WONDAFRASH, B.; ABDISSA, A. Antimicrobial resistance profile of
Enterococcus species isolated from intestinal tracts of hospitalized patients in Jimma,
Ethiopia. BMC Research Notes, England, v. 8, n. 1, 3 jun. 2015. DOI: 10.1186/s13104-
015-1200-2.
106. MONTICELLI, J. et al. Clinical management of non-faecium non-faecalis vancomycinresistant enterococci infection. Focus on Enterococcus gallinarum and Enterococcus
casseliflavus/flavescens. Journal of infection and chemotherapy: official journal of the
Japan Society of Chemotherapy, Netherlands, v. 24, n. 4, p. 237–246, 2018.
107. MOTIE, I. et al. Acinetobacter radioresistens and Enterococcus casseliflavus co-infection
with endocarditis, bacteremia, and pneumonia. IDCases, v. 30, p. e01622–e01622, 1 jan.
2022. DOI: 10.1016/j.idcr.2022.e01622.
108. NZANA, V. B. et al. Twenty-One Episodes of Peritonitis in a Continuous Ambulatory
Peritoneal Dialysis Patient: What is the Root Cause? Indian Journal of Medical
Microbiology, United States, v. 36, n. 2, p. 282–284, 1 abr. 2018.
109. KHURANA, R. N. Enterococcus casseliflavus Endophthalmitis Associated With a Horse
Tail Injury. Archives of Ophthalmology, United States, v. 127, n. 11, p. 1547, 9 nov.
2009.
110. STEPHENS, A.; SIVAPATHASUNTHARAM, C.; JAMES, H. K. Monocular loss of
vision following an open tibial fracture: a case of Enterococcus casseliflavus endogenous
endophthalmitis. BMJ Case Reports, England v. 14, n. 4, p. e241292–e241292, 1 abr.
2021. DOI: 10.1136/bcr-2020-241292.
111. IARIA, C. et al. Enterococcal meningitis caused by Enterococcus casseliflavus. First case
report. BMC Infectious Diseases, England, v. 5, n. 1, 14 jan. 2005.
112. STEFANETTI, V. et al. Detection and DNA quantification of Enterococcus casseliflavus
in a foal with septic meningitis. Journal of the American Veterinary Medical
Association, United States v. 249, n. 1, p. 96–100, 16 jun. 2016. DOI:
10.2460/javma.249.1.96.
113. DOS SANTOS, G. S. et al. Polymicrobial Septic Peritonitis Caused by Enterococcus
faecium and Enterococcus casseliflavus following Uterine Rupture in a Goat. Veterinary
Sciences, Switzerland, v. 11, n. 6, p. 268–268, 12 jun. 2024. DOI:
10.3390/vetsci11060268.
73
114. COSTA, J. L. DA S. et al. Perfil de sensibilidade a antibióticos de isolados animais de
Enterococcus hirae e Enterococcus casseliflavus. Revista de Ciências Médicas e
Biológicas, Salvador, v. 23, n. 3, 9 jan. 2025. DOI:
https://doi.org/10.9771/cmbio.v23i3.64806
115. CHAJĘCKA-WIERZCHOWSKA, W.; ZADERNOWSKA, A.; ŁANIEWSKATROKENHEIM, Ł. Diversity of Antibiotic Resistance Genes in Enterococcus Strains
Isolated from Ready-to-Eat Meat Products. Journal of Food Science, United States, v. 81,
n. 11, p. M2799–M2807, 25 out. 2016.
116. GACA, A. O.; LEMOS, J. A. Adaptation to Adversity: the Intermingling of Stress
Tolerance and Pathogenesis in Enterococci. Microbiology and Molecular Biology
Reviews, United States, v. 83, n. 3, 21 ago. 2019.
117. ABOUZAID, ZAHRAA AL A.; AL-AZEEM, M. W. A.; MOHAMED, H. M. A.
Molecular detection of virulence and resistance genes of Enterococcus species isolated
from milk and milk products. SVU- International Journal of Veterinary Sciences,
Egypt, v. 5, n. 3, p. 1–17, 8 jul. 2022. DOI: 10.21608/svu.2022.126055.1182.
118. CERCENADO, E. et al. Characterization of vancomycin resistance in Enterococcus
durans. Journal of Antimicrobial Chemotherapy, London, v. 36, n. 5, p. 821–825, 1 jan.
1995.
119. WATANABE, S. et al. Genetic Diversity of Enterococci Harboring the High-Level
Gentamicin Resistance Geneaac(6′)-Ie-aph(2″)-Iaoraph(2″)-Iein a Japanese Hospital.
Microbial Drug Resistance, England, v. 15, n. 3, p. 185–194, set. 2009.
120. PADMASINI, E.; PADMARAJ, R.; RAMESH, S. S. High Level Aminoglycoside
Resistance and Distribution of Aminoglycoside Resistant Genes among Clinical Isolates of
Enterococcus Species in Chennai, India. The Scientific World Journal, United States, v.
2014, p. 1–5, 2014.
121. YASLIANI, S. et al. Linezolid vancomycin resistant Enterococcus isolated from clinical
samples in Tehran hospitals. Indian J. Med. Sci., Mumbai, v. 63, n. 7, p. 297–302, jun.
2009.
122. CAUWERTS, K. et al. High prevalence of tetracycline resistance in Enterococcus isolates
from broilers carrying theerm(B) gene. Avian Pathology, United Kingdom, v. 36, n. 5, p.
395–399, out. 2007. DOI: 10.1080/03079450701589167.
123. FRAZZON, A. P. G. et al. Prevalence of antimicrobial resistance and molecular
characterization of tetracycline resistance mediated by tet(M) and tet(L) genes in
Enterococcus spp. isolated from food in Southern Brazil. World Journal of Microbiology
and Biotechnology, Germany, v. 26, n. 2, p. 365–370, 29 ago. 2009.
124. CATTOIR, V.; LECLERCQ, R. Resistance to Macrolides, Lincosamides, and
Streptogramins. In: MAYERS, D. et al. (Eds.). Antimicrobial Drug Resistance. [s.l.]:
Springer, Cham, 2017. p. 269–280.
125. REHMAN, M. A. et al. Genotypes and Phenotypes of Enterococci Isolated From Broiler
Chickens. Frontiers in Sustainable Food Systems, Switzerland, v. 2, 13 dez. 2018.
126. CHO, S. et al. Antimicrobial Resistance Gene Detection and Plasmid Typing Among
Multidrug Resistant Enterococci Isolated from Freshwater Environment. Microorganisms,
Basel, v. 8, n. 9, p. 1338, 2 set. 2020.
74
127. COCCITTO, S. N. et al. Identification of plasmids co-carrying cfr(D)/optrA and
cfr(D2)/poxtA linezolid resistance genes in two Enterococcus avium isolates from swine
brain. Veterinary Microbiology, Netherlands, v. 282, p. 109749–109749, abr. 2023. DOI:
10.1016/j.vetmic.2023.109749.
128. BRIDGE, P. D.; SNEATH, P. H. A. Streptococcus gallinarum sp. nov. and Streptococcus
oralis sp. nov. International Journal of Systematic Bacteriolo, Bethesda, v. 32, n. 4, p.
410–415, out. 1982.
129. LIU, Y. et al. First report of multiresistance gene cfr in Enterococcus species casseliflavus
and gallinarum of swine origin. Veterinary Microbiology, Netherlands, v. 170, n. 3-4, p.
352–357, jun. 2014.
130. SHARIFZADEH PEYVASTI, V. et al. High-level aminoglycoside resistance and
distribution of aminoglycoside resistance genes among Enterococcus spp. clinical isolates
in Tehran, Iran. Journal of Global Antimicrobial Resistance, Netherlands, v. 20, p. 318–
323, mar. 2020. DOI: 10.1016/j.jgar.2019.08.008.
131. DIAS, M. T. A. et al. Enterococcus gallinarum Causing Native Valve Endocarditis.
European Journal of Case Reports in Internal Medicine, Italy, v. 6, n. 3, p. 1, 11 mar.
2019.
132. REID, K. C.; COCKERILL, F. R.; PATEL, R. Clinical and Epidemiological Features of
Enterococcus casseliflavus/flavescens and Enterococcus gallinarum Bacteremia: A Report
of 20 Cases. Clinical Infectious Diseases, United States, v. 32, n. 11, p. 1540–1546, 1 jun.
2001.
133. FRIEDMAN, G. et al. Enterococcal Bacteremia in Children With Malignancies and
Following Hematopoietic Stem Cell Transplantation. The Pediatric Infectious Disease
Journal, United States, v. 39, n. 4, p. 318–324, 28 jan. 2020.
134. TAKAYAMA, Y.; SUNAKAWA, K.; AKAHOSHI, T. Meningitis caused by
Enterococcus gallinarum in patients with ventriculoperitoneal shunts. Journal of Infection
and Chemotherapy, Netherlands, v. 9, n. 4, p. 348–350, 1 jan. 2003.
135. NARCISO-SCHIAVON, J. L. et al. Enterococcus casseliflavus and Enterococcus
gallinarum as causative agents of spontaneous bacterial peritonitis. Annals of Hepatology,
Mexico, v. 14, n. 2, p. 270–272, mar. 2015.
136. HILLIER, R. J. et al. Post-traumatic vancomycin-resistant enterococcal endophthalmitis.
Journal of Ophthalmic Inflammation and Infection, Germany, v. 3, n. 1, p. 42, 2013.
137. DI CESARE, A. et al. Antibiotic-Resistant Enterococci in Seawater and Sediments from a
Coastal Fish Farm. Microbial Drug Resistance, England, v. 18, n. 5, p. 502–509, 1 out.
2012.
138. KOBAYASHI, N. et al. Distribution of aminoglycoside resistance genes in recent clinical
isolates of Enterococcus faecalis, Enterococcus faecium and Enterococcus avium.
Epidemiology and Infection, England, v. 126, n. 2, p. 197–204, abr. 2001. DOI:
10.1017/s0950268801005271.
139. FATOBA, D. O. et al. Genomic analysis of antibiotic-resistant Enterococcus spp. reveals
novel enterococci strains and the spread of plasmid-borne Tet(M), Tet(L) and Erm(B)
genes from chicken litter to agricultural soil in South Africa. Journal of Environmental
Management, England, v. 302, n. Pt B, p. 114101–114101, 15 jan. 2022.
75
140. KAPLAN, A. H.; GILLIGAN, P. H.; FACKLAM, R. R. Recovery of resistant enterococci
during vancomycin prophylaxis. Journal of Clinical Microbiology, United States, v. 26,
n. 6, p. 1216–1218, 1 jun. 1988.
141. HASHIMOTO, Y. et al. First Report of the Local Spread of Vancomycin-Resistant
Enterococci Ascribed to the Interspecies Transmission of a vanA Gene Cluster-Carrying
Linear Plasmid. MSphere, United States, v. 5, n. 2, 29 abr. 2020. DOI:
10.1128/mSphere.00102-20.
142. FREITAS, A. R. et al. Non-susceptibility to tigecycline in enterococci from hospitalised
patients, food products and community sources. International Journal of Antimicrobial
Agents, Netherlands, v. 38, n. 2, p. 174–176, ago. 2011.
143. PORTILLO, A. et al. Macrolide Resistance Genes in Enterococcus spp. Antimicrobial
Agents and Chemotherapy, United States, v. 44, n. 4, p. 967–971, 1 abr. 2000.
144. YOUNUS, Z. et al. Genomic-based characterization of Enterococcus spp.: an emerging
pathogen isolated from human gut. Molecular Biology Reports, Netherlands, v. 48, n. 6,
p. 5371–5376, jun. 2021.
145. FARROW, J. A. E.; COLLINS, M. D. Enterococcus hirae, a New Species That Includes
Amino Acid Assay Strain NCDO 1258 and Strains Causing Growth Depression in Young
Chickens. International journal of systematic bacteriology, Bethesda, v. 35, n. 1, p. 73–
75, 1985.
146. ETHERIDGE, M. E.; YOLKEN, R. H.; VONDERFECHT, S. L. Enterococcus hirae
implicated as a cause of diarrhea in suckling rats. Journal of Clinical Microbiology,
United States, v. 26, n. 9, p. 1741–1744, 1988.
147. DEVRIESE, L.; HAESEBROUCK, F. Enterococcus hirae in different animal species.
Veterinary Record, England, v. 129, n. 17, p. 391–392, 26 out. 1991. DOI:
10.1136/vr.129.17.391.
148. DEVRIESE, L. et al. Enterococcus hirae in septicaemia of psittacine birds. Veterinary
Record, England, v. 130, n. 25, p. 558–559, 20 jun. 1992. DOI: 10.1136/vr.130.25.558.
149. GORDON, S. et al. Antimicrobial susceptibility patterns of common and unusual species
of enterococci causing infections in the United States. Journal of Clinical Microbiology,
United States, v. 30, n. 9, p. 2373–2378, 1992.
150. MCNAMARA, E. B.; KING, E. M.; SMYTH, E. G. A survey of antimicrobial
susceptibility of clinical isolates of Enterococcus spp. from Irish hospitals. Journal of
Antimicrobial Chemotherapy, London, v. 35, n. 1, p. 185–189, 1 jan. 1995.
151. VANDAMME, P. et al. Survey of enterococcal susceptibility patterns in Belgium. Journal
of Clinical Microbiology, United States, v. 34, n. 10, p. 2572–2576, 1 out. 1996. DOI:
10.1128/jcm.34.10.2572-2576.1996.
152. PRAKASH, V. P.; RAO, S. R.; PARIJA, S. C. Emergence of unusual species of
enterococci causing infections, South India. BMC Infectious Diseases, England, v. 5, n. 1,
17 mar. 2005. DOI: 10.1186/1471-2334-5-14.
153. BILEK, H. C. et al. Enterococcus hirae as a cause of bacteremic urinary tract infection:
first case report from Turkey. The Journal of Infection in Developing Countries, Italy, v.
14, n. 12, p. 1780–1482, 30 dez. 2020.
76
154. BOURAFA, N. et al. Enterococcus hirae, an unusual pathogen in humans causing urinary
tract infection in a patient with benign prostatic hyperplasia: first case report in Algeria.
New Microbes and New Infections, United Kingdom, v. 8, p. 7–9, 17 ago. 2015. DOI:
10.1016/j.nmni.2015.08.003.
155. POYART, C. et al. Native Valve Endocarditis Due to Enterococcus hirae. Journal of
Clinical Microbiology, United States, v. 40, n. 7, p. 2689–2690, 1 jul. 2002.
156. WINTHER, M. et al. First Danish case of infective endocarditis caused by Enterococcus
hirae. BMJ Case Reports, England, v. 13, n. 12, p. e237950–e237950, 1 dez. 2020.
157. MERLO, J.; BUSTAMANTE, G.; LLIBRE, J. M. Bacteremic pneumonia caused by
Enterococcus hirae in a subject receiving regorafenib. Enfermedades Infecciosas y
Microbiología Clínica, Spain, v. 38, n. 5, p. 226–229, maio 2020. DOI:
10.1016/j.eimc.2019.06.002.
158. GILAD, J. et al. Enterococcus hirae Septicemia in a Patient with End-Stage Renal Disease
Undergoing Hemodialysis. European Journal of Clinical Microbiology & Infectious
Diseases, German,y v. 17, n. 8, p. 576–577, 21 set. 1998.
159. BRULÉ, N. et al. Life-threatening bacteremia and pyonephrosis caused by Enterococcus
hirae. Médecine et Maladies Infectieuses, France, v. 43, n. 9, p. 401–402, set. 2013. DOI:
10.1016/j.medmal.2013.07.002.
160. NAKAMURA, T. et al. Enterococcus hirae bacteremia associated with acute
pyelonephritis in a patient with alcoholic cirrhosis: a case report and literature review.
BMC Infectious Diseases, England, v. 21, n. 1, 23 set. 2021. DOI: 10.1186/s12879-021-
06707-2.
161. CHAN, T. S. et al. Enterococcus hirae‐related acute pyelonephritis and cholangitis with
bacteremia: An unusual infection in humans. The Kaohsiung journal of medical sciences,
Taiwan, v. 28, n. 2, p. 111–114, 10 set. 2011.
162. BICEGO-PEREIRA, E. C. et al. Evaluation of the presence of microorganisms from root
canal of teeth submitted to retreatment due to prosthetic reasons and without evidence of
apical periodontitis. Clinical Oral Investigations, v. 24, n. 9, p. 3243–3254, 20 jan. 2020.
DOI: 10.1007/s00784-020-03200-z.
163. MEREI, F. et al. A unusual case of multifocal pyogenic abscess formation following ERCP
procedure. BMC Surgery, [s.l], v. 20, n. 1, 6 maio 2020.
164. SIM, J. S. et al. Spontaneous Bacterial Peritonitis with Sepsis Caused by Enterococcus
hirae. Journal of Korean Medical Science, Weekly, v. 27, n. 12, p. 1598–1598, 1 jan.
2012. DOI: 10.3346/jkms.2012.27.12.1598.
165. VAN LOON, A. C. J. et al. Infective vegetative endocarditis of the mitral, aortic, and
pulmonary valves due to Enterococcus hirae in a cat with a ventricular septal defect.
Journal of Veterinary Cardiology, Netherlands, v. 30, p. 69–76, 1 ago. 2020. DOI:
10.1016/j.jvc.2020.05.005.
166. LAPOINTE, J. M. et al. Enterococcus hirae Enteropathy with Ascending Cholangitis and
Pancreatitis in a Kitten. Veterinary Pathology, United States, v. 37, n. 3, p. 282–284, 1
maio 2000.
167. NICKLAS, J. L. et al. In Situ Molecular Diagnosis and Histopathological Characterization
of Enteroadherent Enterococcus hirae Infection in Pre-Weaning-Age Kittens. Journal of
Clinical Microbiology, United States, v. 48, n. 8, p. 2814–2820, 3 jun. 2010.
77
168. GHOSH, A. et al. Resident Cats in Small Animal Veterinary Hospitals Carry Multi-Drug
Resistant Enterococci and are Likely Involved in Cross-Contamination of the Hospital
Environment. Frontiers in Microbiology, Switzerland v. 3, 2012. DOI:
10.3389/fmicb.2012.00062.
169. HUMMEL, A.; HOLZAPFEL, W. H.; FRANZ, C. M. A. P. Characterisation and transfer
of antibiotic resistance genes from enterococci isolated from food. Systematic and
Applied Microbiology, Germany, v. 30, n. 1, p. 1–7, jan. 2007.
170.JACKSON, C. R. et al. Prevalence of streptogramin resistance in enterococci from
animals: identification of vatD from animal sources in the USA. International Journal of
Antimicrobial Agents, Netherlands, v. 30, n. 1, p. 60–66, jul. 2007.
171. CHO, S. et al. Diversity and antimicrobial resistance of Enterococcus from the Upper
Oconee Watershed, Georgia. Journal of Applied Microbiology, England, v. 128, n. 4, p.
1221–1233, 1 abr. 2020.
172. BACCANI, I. et al. Detection of poxtA2, a Presumptive poxtA Ancestor, in a Plasmid
from a Linezolid-Resistant Enterococcus gallinarum Isolate. Antimicrobial Agents and
Chemotherapy, United States, v. 65, n. 8, p. e0069521, 2021. DOI: 10.1128/AAC.00695-
21.
173. MOELLERING, R. C. Emergence of Enterococcus as a Significant Pathogen. Clinical
Infectious Diseases, United States, v. 14, n. 6, p. 1173–1178, 1 jun. 1992.
174. GILMORE, M. S. (ED.). The Enterococci: pathogenesis, molecular biology, and
antibiotic resistance. Washington, DC: ASM Press, 2002. p. 1–416.
175. YUAN, T. et al. Virulence genes and antimicrobial resistance in Enterococcus strains
isolated from dogs and cats in Northeast China. Journal of Veterinary Medical Science,
Japan, v. 85, n. 3, p. 371–378, 1 jan. 2023. DOI: 10.1292/jvms.22-0410.
176. TOLEDO-ARANA, A. et al. The Enterococcal Surface Protein, Esp, Is Involved in
Enterococcus faecalis Biofilm Formation. Applied and Environmental Microbiology,
United States, v. 67, n. 10, p. 4538–4545, 1 out. 2001.
177. TAGLIALEGNA, A. et al. The biofilm-associated surface protein Esp of Enterococcus
faecalis forms amyloid-like fibers. npj Biofilms and Microbiomes, United States, v. 6, n.
1, 27 mar. 2020.
178. NALLAPAREDDY, S. R.; SINGH, K. V.; MURRAY, B. E. Contribution of the Collagen
Adhesin Acm to Pathogenesis of Enterococcus faecium in Experimental Endocarditis.
Infection and Immunity, United States, v. 76, n. 9, p. 4120–4128, 30 jun. 2008.
179. SINGH, K. V. et al. Importance of the Collagen Adhesin Ace in Pathogenesis and
Protection against Enterococcus faecalis Experimental Endocarditis. PLoS Pathogens,
United States, v. 6, n. 1, p. e1000716, 8 jan. 2010.
180. DUNNY, G. M.; LEONARD, B. A.; HEDBERG, P. J. Pheromone-inducible conjugation
in Enterococcus faecalis: interbacterial and host-parasite chemical communication.
Journal of Bacteriology, United States, v. 177, n. 4, p. 871–876, fev. 1995.
181. RAKITA, R. M. et al. Enterococcus faecalis Bearing Aggregation Substance Is Resistant
to Killing by Human Neutrophils despite Phagocytosis and Neutrophil Activation.
Infection and Immunity, United States, v. 67, n. 11, p. 6067–6075, 1 nov. 1999.
78
182. SINGH, K. V.; NALLAPAREDDY, S. R.; MURRAY, B. E. Importance of the Ebp
(Endocarditis and Biofilm-Associated Pilus) Locus in the Pathogenesis of Enterococcus
faecalis Ascending Urinary Tract Infection. The Journal of Infectious Diseases, United
States, v. 195, n. 11, p. 1671–1677, 1 jun. 2007.
183. NALLAPAREDDY, S. R. et al. Conservation of Ebp-Type Pilus Genes among
Enterococci and Demonstration of Their Role in Adherence of Enterococcus faecalis to
Human Platelets. Infection and Immunity, United States, v. 79, n. 7, p. 2911–2920, jul.
2011.
184. LA ROSA, S. L. et al. Enterococcus faecalis Ebp pili are important for cell-cell
aggregation and intraspecies gene transfer. Microbiology, England, v. 162, n. 5, p. 798–
802, 1 maio 2016.
185. HUYCKE, M. M. et al. Bacteremia caused by hemolytic, high-level gentamicin-resistant
Enterococcus faecalis. Antimicrobial Agents and Chemotherapy, United States, v. 35, n.
8, p. 1626–1634, ago. 1991.
186.JETT, B. D. et al. Contribution of the pAD1-encoded cytolysin to the severity of
experimental Enterococcus faecalis endophthalmitis. Infection and Immunity, United
States, v. 60, n. 6, p. 2445–2452, 1992.
187.JUNG, A. et al. A Review of Enterococcus cecorum Infection in Poultry. Avian Diseases,
United States, v. 62, n. 3, p. 261–271, set. 2018.
188. AVBERŠEK, J. et al. Surveillance of the source of poultry infections with Enterococcus
hirae and Enterococcus cecorum in Slovenia and E. hirae antibiotic resistance patterns.
PubMed, [s.l], v. 44, n. 4, p. 210–216, out. 2021.
189. PARK, S. Y. et al. Extracellular Gelatinase of Enterococcus faecalis Destroys a Defense
System in Insect Hemolymph and Human Serum. Infection and Immunity, United States,
v. 75, n. 4, p. 1861–1869, 29 jan. 2007. DOI: 10.1128/IAI.01473-06.
190. THURLOW, L. R. et al. Gelatinase Contributes to the Pathogenesis of Endocarditis Caused
by Enterococcus faecalis. Infection and Immunity, United States, v. 78, n. 11, p. 4936–
4943, ago. 2010.
191. MACOVEI, L. et al. Enterococcus faecalis with the gelatinase phenotype regulated by the
fsr operon and with biofilm‐forming capacity are common in the agricultural environment.
Environmental Microbiology, England, v. 11, n. 6, p. 1540–1547, 31 maio 2009.
192. KAYAOGLU, G.; ØRSTAVIK, D. Virulence factors of Enterococcus faecalis:
relationship to endodontic disease. Critical Reviews in Oral Biology and Medicine: An
Official Publication of the American Association of Oral Biologists, United States, v.
15, n. 5, p. 308–320, 1 set. 2004. DOI: 10.1177/154411130401500506.
193. CHANDLER, J. R.; DUNNY, G. M. Enterococcal peptide sex pheromones: synthesis and
control of biological activity. Peptides, [s.l], v. 25, n. 9, p. 1377–1388, set. 2004.
194. SANNOMIYA, P. et al. Characterization of a class of nonformylated Enterococcus
faecalis-derived neutrophil chemotactic peptides: the sex pheromones. Proceedings of the
National Academy of Sciences, United States, v. 87, n. 1, p. 66–70, 1990. DOI:
10.1073/pnas.87.1.66.
195. EMBER, J. A.; HUGLI, T. E. Characterization of the human neutrophil response to sex
pheromones from Streptococcus faecalis. PubMed, [s.l], v. 134, n. 4, p. 797–805, 1989.
79
196. NALLAPAREDDY, S. R.; MURRAY, B. E. Ligand-Signaled Upregulation of
Enterococcus faecalis ace Transcription, a Mechanism for Modulating Host-E. faecalis
Interaction. Infection and Immunity, United States, v. 74, n. 9, p. 4982–4989, set. 2006.
197. MOHAMED, J. A. et al. Influence of Origin of Isolates, Especially Endocarditis Isolates,
and Various Genes on Biofilm Formation by Enterococcus faecalis. Infection and
Immunity, United States, v. 72, n. 6, p. 3658–3663, jun. 2004.
198. LEWIS, K. Riddle of Biofilm Resistance. Antimicrobial Agents and Chemotherapy,
United States, v. 45, n. 4, p. 999–1007, 2001. DOI: 10.1128/AAC.45.4.999-1007.2001.
199. HUYCKE, M. M.; JOYCE, W.; WACK, M. F. Augmented Production of Extracellular
Superoxide by Blood Isolates of Enterococcus faecalis. Journal of Infectious Diseases, v.
United States, 173, n. 3, p. 743–745, mar. 1996.
200. HUYCKE, M. M.; ABRAMS, V.; MOORE, D. R. Enterococcus faecalis produces
extracellular superoxide and hydrogen peroxide that damages colonic epithelial cell DNA.
Carcinogenesis, [s.l.], v. 23, n. 3, p. 529–536, mar. 2002.
201. HUYCKE, M. M. et al. Extracellular superoxide production by Enterococcus faecalis
requires demethylmenaquinone and is attenuated by functional terminal quinol oxidases.
Molecular Microbiology, United States, v. 42, n. 3, p. 729–740, 7 jul. 2008. DOI:
10.1046/j.1365-2958.2001.02638.x.
202. HUYCKE, M. M.; GILMORE, M. S. In Vivo Survival of Enterococcus faecalis is
Enhanced by Extracellular Superoxide Production. In: HORAUD, T. et al. (Eds.).
Streptococci and the Host. Boston, MA: Springer, 1997. p. 781–784.
203. BIZZINI, A. et al. The Enterococcus faecalis superoxide dismutase is essential for its
tolerance to vancomycin and penicillin. Journal of Antimicrobial Chemotherapy,
London, v. 64, n. 6, p. 1196–1202, 14 out. 2009. DOI: 10.1093/jac/dkp369.
204. BAUREDER, M.; REIMANN, R.; HEDERSTEDT, L. Contribution of catalase to
hydrogen peroxide resistance in Enterococcus faecalis. FEMS Microbiology Letters,
England, v. 331, n. 2, p. 160–164, jun. 2012.
205. GIVENS BELL, S. Antibiotic Resistance: Is the End of an Era Near? Neonatal Network,
Bethesda, v. 22, n. 6, p. 47–54, jan. 2003. DOI: 10.1891/0730-0832.22.6.47.
206. WERNER, G. et al. Emergence and spread of vancomycin resistance among enterococci in
Europe. Eurosurveillance, Sweden, v. 13, n. 47, p. 19046, 20 nov. 2008.
207. PRABAKER, K.; WEINSTEIN, R. A. Trends in antimicrobial resistance in intensive care
units in the United States. Current Opinion in Critical Care, United States, v. 17, n. 5, p.
472–479, out. 2011. DOI: 10.1097/MCC.0b013e32834a4b03.
208. ALAGNA, L. et al. Multidrug-Resistant Gram-Negative Bacteria Decolonization in
Immunocompromised Patients: A Focus on Fecal Microbiota Transplantation.
International Journal of Molecular Sciences, Switzerland, v. 21, n. 16, p. 5619, 5 ago.
2020.
209. SUNDSFJORD, A.; SIMONSEN, G. S.; COURVALIN, P. Human infections caused by
glycopeptide-resistant Enterococcus spp: are they a zoonosis? Clinical Microbiology and
Infection: The Official Publication of the European Society of Clinical Microbiology
and Infectious Diseases, England, v. 7, n. s4, p. 16–33, 2001.
80
210. RAZA, T.; ULLAH, S. R.; MEHMOOD, K. Vancomycin resistant Enterococci: A brief
review. The Journal of the Pakistan Medical Association, Pakistan v. 68, n. 5, p. 768–
772, maio 2018.
211. ANTUNES, P. et al. Salmonellosis: the role of poultry meat. Clinical Microbiology and
Infection, England, v. 22, n. 2, p. 110–121, fev. 2016. DOI: 10.1016/j.cmi.2015.12.004.
212. SKARP, C. P. A.; HÄNNINEN, M. L.; RAUTELIN, H. I. K. Campylobacteriosis: the role
of poultry meat. Clinical Microbiology and Infection, England, v. 22, n. 2, p. 103–109,
fev. 2016. DOI: 10.1016/j.cmi.2015.11.019.
213. PHILLIPS, I. Does the use of antibiotics in food animals pose a risk to human health? A
critical review of published data. Journal of Antimicrobial Chemotherapy, London, v.
53, n. 1, p. 28–52, 4 dez. 2003. DOI: 10.1093/jac/dkg483.
214. ISEPPI, R. et al. Antimicrobial resistance and virulence traits in Enterococcus strains
isolated from dogs and cats. PubMed, [s.l], v. 38, n. 3, p. 369–78, jul. 2015.
215. OVERGAAUW, P. A. M. et al. A One Health Perspective on the Human–Companion
Animal Relationship with Emphasis on Zoonotic Aspects. International Journal of
Environmental Research and Public Health, Switzerland, v. 17, n. 11, p. 3789, maio
2020.
216. ARIAS, C. A.; CONTRERAS, G. A.; MURRAY, B. E. Management of multidrug-resistant
enterococcal infections. Clinical Microbiology and Infection, England, v. 16, n. 6, p.
555–562, jun. 2010. DOI: 10.1111/j.1469-0691.2010.03214.x.
217.JAWETZ, E.; SONNE, M. Penicillin-Streptomycin Treatment of Enterococcal
Endocarditis. New England Journal of Medicine, United States, v. 274, n. 13, p. 710–
715, 31 mar. 1966.
218. BADDOUR, L. M. et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial
Therapy, and Management of Complications: A Scientific Statement for Healthcare
Professionals From the American Heart Association. Circulation, United States, v. 132, n.
15, p. 1435–1486, 13 out. 2015. DOI: 10.1161/CIR.0000000000000296.
219. GERACI, J. E.; MARTIN, W. J. Antibiotic Therapy of Bacterial Endocarditis.
Circulation, United States, v. 10, n. 2, p. 173–194, ago. 1954.
220. MOELLERING, R. C.; WEINBERG, A. N. Studies on antibiotic synergism against
enterococci. Journal of Clinical Investigation, United States, v. 50, n. 12, p. 2580–2584,
dez. 1971. DOI: 10.1172/JCI106758.
221. PINTADO, V. et al. Enterococcal Meningitis: A Clinical Study of 39 Cases and Review of
the Literature. Medicine, [s.l], v. 82, n. 5, p. 346–364, set. 2003.
222. FREITAS, A. R. et al. High rates of colonisation by ampicillin-resistant enterococci in
residents of long-term care facilities in Porto, Portugal. International Journal of
Antimicrobial Agents, Netherlands, v. 51, n. 3, p. 503–507, mar. 2018.
223. GOEL, V. et al. Community Acquired Enterococcal Urinary Tract Infections and
Antibiotic Resistance Profile in North India. Journal of Laboratory Physicians,
Germany, v. 8, n. 01, p. 050–054, jun. 2016. DOI: 10.4103/0974-2727.176237.
224. WOEGERBAUER, M. et al. Prevalence of the aminoglycoside phosphotransferase genes
aph(3′)-IIIa and aph(3′)-IIa in Escherichia coli, Enterococcus faecalis, Enterococcus
faecium, Pseudomonas aeruginosa, Salmonella enterica subsp. enterica and
81
Staphylococcus aureus isolates in Austria. Journal of Medical Microbiology, England, v.
63, n. Pt 2, p. 210–217, fev. 2014.
225. SMITH, J. R. et al. β -Lactam combinations with daptomycin provide synergy against
vancomycin-resistant Enterococcus faecalis and Enterococcus faecium. Journal of
Antimicrobial Chemotherapy, London, v. 70, n. 6, p. 1738–1743, 1 fev. 2015.
226. YIM, J.; SMITH, J. R.; RYBAK, M. J. Role of Combination Antimicrobial Therapy for
Vancomycin-Resistant Enterococcus faecium Infections: Review of the Current Evidence.
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, United
States, v. 37, n. 5, p. 579–592, maio 2017. DOI: 10.1002/phar.1922.
227. CHOICE of antibacterial drugs. Treat Guidel Med Lett., [s.l], v. 5, n. 57, p. 33–50, maio
2007.
228. MILLER, W. R. et al. Mechanisms of antibiotic resistance in enterococci. Expert Review
of Anti-infective Therapy, England, v. 12, n. 10, p. 1221–1236, out. 2014.
229. FERNÁNDEZ-HIDALGO, N.; ESCOLÀ-VERGÉ, L. Enterococcus faecalis Bacteremia.
Journal of the American College of Cardiology, United States, v. 74, n. 2, p. 202–204,
16 jul. 2019.
230. HASSAN, R. M. et al. Reduced susceptibility of Enterococcus spp. isolates from Cairo
University Hospital to tigecycline: Highlight on the influence of proton pump inhibitors.
Journal of Global Antimicrobial Resistance, Netherlands, v. 12, p. 68–72, mar. 2018.
231. BUTAYE, P.; DEVRIESE, L. A.; HAESEBROUCK, F. Differences in Antibiotic
Resistance Patterns of Enterococcus faecalis and Enterococcus faecium Strains Isolated
from Farm and Pet Animals. Antimicrobial Agents and Chemotherapy, United States, v.
45, n. 5, p. 1374–1378, maio 2001. DOI: 10.1128/AAC.45.5.1374-1378.2001.
232.JENSEN, L. B.; FRIMODT-MØLLER, N.; AARESTRUP, F. M. Presence of erm gene
classes in gram-positive bacteria of animal and human origin in Denmark. FEMS
microbiology letters, England, v. 170, n. 1, p. 151–158, 1 jan. 1999. DOI: 10.1111/j.1574-
6968.1999.tb13368.x.
233. ARSÈNES.; LECLERCQ, R. Role of a qnr-Like Gene in the Intrinsic Resistance of
Enterococcus faecalis to Fluoroquinolones. Antimicrobial Agents and Chemotherapy,
United States, v. 51, n. 9, p. 3254–3258, 9 jul. 2007. DOI: 10.1128/AAC.00274-07.
234. SINEL, C. et al. Subinhibitory Concentrations of Ciprofloxacin Enhance Antimicrobial
Resistance and Pathogenicity of Enterococcus faecium. Antimicrobial Agents and
Chemotherapy, United States, v. 61, n. 5, p. e02763-16, 24 abr. 2017.
235. EL AMIN, N.; JALAL, S.; WRETLIND, B. Alterations in GyrA and ParC Associated with
Fluoroquinolone Resistance in Enterococcus faecium. Antimicrobial Agents and
Chemotherapy, United States, v. 43, n. 4, p. 947–949, abr. 1999. DOI:
10.1128/AAC.43.4.947.
236.JONAS, B. M.; MURRAY, B. E.; WEINSTOCK, G. M. Characterization of emeA, a norA
Homolog and Multidrug Resistance Efflux Pump, in Enterococcus faecalis. Antimicrobial
Agents and Chemotherapy, United States, v. 45, n. 12, p. 3574–3579, dez. 2001.
237. MIRZAII, M. et al. Antibiotic resistance assessment and multi-drug efflux pumps of
Enterococcus faecium isolated from clinical specimens. Journal of Infection in
Developing Countries, Italy, v. 17, n. 05, p. 649–655, 31 maio 2023.
82
238. MISHRA, N. N. et al. Daptomycin Resistance in Enterococci Is Associated with Distinct
Alterations of Cell Membrane Phospholipid Content. PLoS ONE, London, v. 7, n. 8, p.
e43958, 2012. DOI: 10.1371/journal.pone.0043958
239. MILLER, W. R.; BAYER, A. S.; ARIAS, C. A. Mechanism of Action and Resistance to
Daptomycin in Staphylococcus aureus and Enterococci. Cold Spring Harbor
Perspectives in Medicine, United States, v. 6, n. 11, p. a026997, 1 nov. 2016.
240. VEGA, S.; DOWZICKY, M. J. Antimicrobial susceptibility among Gram-positive and
Gram-negative organisms collected from the Latin American region between 2004 and
2015 as part of the Tigecycline Evaluation and Surveillance Trial. Annals of Clinical
Microbiology and Antimicrobials, United Kingdom, v. 16, n. 1, p. 50, 12 jul. 2017.
241. LAURIDSEN, T. K. et al. Linezolid as rescue treatment for left-sided infective
endocarditis: an observational, retrospective, multicenter study. European Journal of
Clinical Microbiology & Infectious Diseases, Germany, v. 31, n. 10, p. 2567–2574, out.
2012. DOI: 10.1007/s10096-012-1597-7.
242. MARSHALL, S. H. et al. Gene Dosage and Linezolid Resistance in Enterococcus faecium
and Enterococcus faecalis. Antimicrobial Agents and Chemotherapy, United States, v.
46, n. 10, p. 3334–3336, out. 2002. DOI: 10.1128/AAC.46.10.3334-3336.2002.
243. GAWRYSZEWSKA, I. et al. Linezolid-resistant enterococci in Polish hospitals: species,
clonality and determinants of linezolid resistance. European Journal of Clinical
Microbiology & Infectious Diseases, Germany, v. 36, n. 7, p. 1279–1286, jul. 2017. DOI:
10.1007/s10096-017-2934-7.
244. COCCITTO, S. N. et al. Linezolid-resistant Enterococcus gallinarum isolate of swine
origin carrying cfr, optrA and poxtA genes. Journal of Antimicrobial Chemotherapy, v.
London, 77, n. 2, p. 331–337, 23 nov. 2021. DOI: 10.1093/jac/dkab408.
245. OCHSNER, M. Photophysical and photobiological processes in the photodynamic therapy
of tumours. Journal of Photochemistry and Photobiology B: Biology, Switzerland, v.
39, n. 1, p. 1–18, maio 1997.
246. ACKROYD, R. et al. The History of Photodetection and Photodynamic Therapy.
Photochemistry and Photobiology, [s.l.], v. 74, n. 5, p. 656, 2001. DOI: 10.1562/0031-
8655(2001)074<0656:thopap>2.0.co;2.
247. RAAB, O. Uber die wirkung fluoreszierenden stoffen. Infusaria Zeitschrift Biologie, [s.l],
v. 39, p. 524–546, 1900.
248. FINSEN, N. R. Phototherapy. Londres: Edward Arnold, 1901.
249. ALGORRI, J. F. et al. Photodynamic Therapy: A Compendium of Latest Reviews.
Cancers, [s.l], v. 13, n. 17, p. 4447, 3 set. 2021.
250. CHAMPEAU, M. et al. Photodynamic therapy for skin cancer: How to enhance drug
penetration? Journal of Photochemistry and Photobiology B: Biology, Switzerland, v.
197, p. 111544, ago. 2019. DOI: 10.1016/j.jphotobiol.2019.111544.
251. OLEK, M. et al. Photodynamic therapy for the treatment of oral squamous carcinoma—
Clinical implications resulting from in vitro research. Photodiagnosis and Photodynamic
Therapy, Netherlands, v. 27, p. 255–267, set. 2019.
83
252. BRESSLER, N. M.; BRESSLER, S. B. Photodynamic therapy with verteporfin
(Visudyne): impact on ophthalmology and visual sciences. PubMed, [s.l], v. 41, n. 3, p.
624–8, mar. 2000.
253. BERGMANS, L. et al. Effect of photo-activated disinfection on endodontic pathogens ex
vivo. International Endodontic Journal, England, v. 41, n. 3, p. 227–239, mar. 2008.
DOI: 10.1111/j.1365-2591.2007.01344.x
254. LUI, J.; CORBET, E. F.; JIN, L. Combined photodynamic and low-level laser therapies as
an adjunct to nonsurgical treatment of chronic periodontitis. Journal of Periodontal
Research, United States, v. 46, n. 1, p. 89–96, set. 2010.
255. DAMASCENO, M. C. F.; ARAÚJO, M. M. do C. Photodynamic therapy in endodontics:
literature review. Brazilian Journal of Implantology and Health Sciences, Brazil, v. 3, n.
3, p. 27–40, 7 abr. 2021. DOI: https://doi.org/10.36557/2674-8169.2021v3n3p27-40
256. BOEHNCKE, W. H.; ELSHORST-SCHMIDT, T.; KAUFMANN, R. Systemic
Photodynamic Therapy Is a Safe and Effective Treatment for Psoriasis. Archives of
Dermatology, United States, v. 136, n. 2, p. 271–272, fev. 2000. DOI:
10.1001/archderm.136.2.271.
257. TRAUNER, K. B.; HASAN, T. Photodynamic Treatment of Rheumatoid and
Inflammatory Arthritis. Photochemistry and Photobiology, Switzerland, v. 64, n. 5, p.
740–750, nov. 1996.
258. BARR, H. Barrett’s esophagus: treatment with 5-aminolevulinic acid photodynamic
therapy. Gastrointestinal endoscopy clinics of North America, Bethesda, v. 10, n. 3, p.
421–437, jul. 2000.
259. ROCKSON, S. G. et al. Photoangioplasty. Circulation, United States, v. 102, n. 5, p. 591–
596, ago. 2000.
260.JENKINS, M. et al. Clinical study of adjuvant photodynamic therapy to reduce restenosis
following femoral angioplasty. British Journal of Surgery, England, v. 86, n. 10, p.
1258–1263, out. 1999. DOI: 10.1046/j.1365-2168.1999.01247.x.
261. HUANG, L.; DAI, T.; HAMBLIN, M. R. Antimicrobial Photodynamic Inactivation and
Photodynamic Therapy for Infections. Methods in molecular biology (Clifton, N.J.), v.
635, p. 155–173, 2010. DOI: 10.1007/978-1-60761-697-9_12.
262. PLAETZER, K. et al. Photophysics and photochemistry of photodynamic therapy:
fundamental aspects. Lasers in Medical Science, England, v. 24, n. 2, p. 259–268, 5 fev.
2008.
263. CIEPLIK, F. et al. Antimicrobial photodynamic therapy for inactivation of biofilms formed
by oral key pathogens. Frontiers in Microbiology, Switzerland, v. 5, 12 ago. 2014. DOI:
10.3389/fmicb.2014.00405.
264. GHORBANI, J. et al. Photosensitizers in antibacterial photodynamic therapy: an overview.
Laser Therapy, [s.l], v. 27, n. 4, p. 293–302, 31 dez. 2018.
265. FEKRAZAD, R.; ZARE, H.; VAND, S. M. S. Photodynamic therapy effect on cell growth
inhibition induced by Radachlorin and toluidine blue O on Staphylococcus aureus and
Escherichia coli: An in vitro study. Photodiagnosis and Photodynamic Therapy,
Netherlands, v. 15, p. 213–217, set. 2016.
84
266. FONTANA, C. R. et al. The antibacterial effect of photodynamic therapy in dental plaquederived biofilms. Journal of Periodontal Research, United States, v. 44, n. 6, p. 751–759,
dez. 2009.
267. SHRESTHA, A.; KISHEN, A. Polycationic Chitosan-Conjugated Photosensitizer for
Antibacterial Photodynamic Therapy. Photochemistry and Photobiology, United States,
v. 88, n. 3, p. 577–583, 29 nov. 2011. DOI: 10.1111/j.1751-1097.2011.01026.x.
268. KISHEN, A. et al. Efflux Pump Inhibitor Potentiates Antimicrobial Photodynamic
Inactivation of Enterococcus faecalis Biofilm. Photochemistry and Photobiology, United
States, v. 86, n. 6, p. 1343–1349, 22 set. 2010.
269. TENNERT, C. et al. Effect of photodynamic therapy (PDT) on Enterococcus faecalis
biofilm in experimental primary and secondary endodontic infections. BMC Oral Health,
England, v. 14, n. 1, nov. 2014.
270. LÜTHI, M. et al. Hypericin- and mTHPC-mediated photodynamic therapy for the
treatment of cariogenic bacteria. Medical Laser Application, [s.l], v. 24, n. 4, p. 227–236,
dez. 2009. DOI: https://doi.org/10.1016/j.mla.2009.07.004
271. GARCÍA, I. et al. Antimicrobial photodynamic activity of hypericin against methicillinsusceptible and resistant Staphylococcus aureus biofilms. Future Microbiology, [s.l], v.
10, n. 3, p. 347–356, mar. 2015. DOI: 10.2217/fmb.14.114.
272. MUN, S.-H. et al. Curcumin Reverse Methicillin Resistance in Staphylococcus aureus.
Molecules, Switzerland, v. 19, n. 11, p. 18283–18295, 10 nov. 2014.
273. PERNI, S. et al. Nanoparticles: their potential use in antibacterial photodynamic therapy.
Photochemical & Photobiological Sciences, Switzerland, v. 10, n. 5, p. 712, 2011. DOI:
10.1039/c0pp00360c.
274. MROZ, P. et al. Photodynamic therapy with fullerenes. Photochemical & photobiological
sciences : Official journal of the European Photochemistry Association and the
European Society for Photobiology, [s.l], v. 6, n. 11, p. 1139–1149, 1 nov. 2007.
275. DEI, D. et al. Phthalocyanines as photodynamic agents for the inactivation of microbial
pathogens. Journal of Porphyrins and Phthalocyanines, Singapore, v. 10, n. 03, p. 147–
159, mar. 2006. DOI: https://doi.org/10.1142/S1088424606000181.
276. AMOS-TAUTUA, B.; SONGCA, S.; OLUWAFEMI, O. Application of Porphyrins in
Antibacterial Photodynamic Therapy. Molecules, Switzerland v. 24, n. 13, p. 2456, 4 jul.
2019.
277. LI, F. et al. Metalloporphyrin-Based Biomimetic Catalysis: Applications, Modifications
and Flexible Microenvironment Influences (A Review). Russian Journal of General
Chemistry, Netherlands, v. 93, n. 1, p. 189–214, jan. 2023.
278. NITZAN, Y. et al. Inactivation of Gram-Negative Bacteria by Photosensitized Porphyrins.
Photochemistry and Photobiology, Switzerland, v. 55, n. 1, p. 89–96, jan. 1992.
279. MALIK, Z.; LADAN, H.; NITZAN, Y. Photodynamic inactivation of Gram-negative
bacteria: Problems and possible solutions. Journal of Photochemistry and Photobiology
B: Biology, Switzerland, v. 14, n. 3, p. 262–266, jul. 1992.
280. MERCHAT, M. et al. Meso-substituted cationic porphyrins as efficient photosensitizers of
gram-positive and gram-negative bacteria. Journal of Photochemistry and Photobiology
B-biology, Switzerland, v. 32, n. 3, p. 153–157, 1 fev. 1996.
85
281. MINNOCK, A. et al. Mechanism of Uptake of a Cationic Water-Soluble Pyridinium Zinc
Phthalocyanine across the Outer Membrane of Escherichia coli. Antimicrobial Agents
and Chemotherapy, United States, v. 44, n. 3, p. 522–527, 2000.
282. BANFI, S. et al. Antibacterial activity of tetraaryl-porphyrin photosensitizers: An in vitro
study on Gram negative and Gram positive bacteria. Journal of Photochemistry and
Photobiology B: Biology, Netherlands, v. 85, n. 1, p. 28–38, out. 2006. DOI:
https://doi.org/10.1016/j.jphotobiol.2006.04.00
283. GEORGE, S.; HAMBLIN, M. R.; KISHEN, A. Uptake pathways of anionic and cationic
photosensitizers into bacteria. Photochemical & Photobiological Sciences, Switzerland, v.
8, n. 6, p. 788, 2009.
284. DEMIDOVA, T. N.; HAMBLIN, M. R. Photodynamic Therapy Targeted to Pathogens.
International Journal of Immunopathology and Pharmacology, England, v. 17, n. 3, p.
245–254, set. 2004. DOI: 10.1177/039463200401700304.
285. BAPTISTA, M. S. et al. Type I and Type II Photosensitized Oxidation Reactions:
Guidelines and Mechanistic Pathways. Photochemistry and Photobiology, v. 93, n. 4, p.
912–919, mar. 2017.
286. KONOPKA, K.; GOSLINSKI, T. Photodynamic Therapy in Dentistry. Journal of Dental
Research, v. 86, n. 8, p. 694–707, ago. 2007.
287. MAISCH, T. et al. Photodynamic inactivation of multi-resistant bacteria (PIB) - a new
approach to treat superficial infections in the 21st century. Journal der Deutschen
Dermatologischen Gesellschaft, Germany, v. 9, n. 5, p. 360–366, 1 maio 2011.
288. CONWELL, M.; DOOLEY, J.; NAUGHTON, P. Enterococcal biofilm – a nidus for
antibiotic resistance transfer? Journal of Applied Microbiology, v. 132, n. 5, maio 2022.
289. CASTANO, A. P.; DEMIDOVA, T. N.; HAMBLIN, M. R. Mechanisms in photodynamic
therapy: part one—photosensitizers, photochemistry and cellular localization.
Photodiagnosis and Photodynamic Therapy, Netherlands, v. 1, n. 4, p. 279–293, dez.
2004.
290. HAMBLIN, M. R.; HASAN, T. Photodynamic therapy: a new antimicrobial approach to
infectious disease? Photochemical & Photobiological Sciences, v. 3, n. 5, p. 436, 2004.
291. VERA, D. M. et al. Strategies to Potentiate Antimicrobial Photoinactivation by
Overcoming Resistant Phenotypes†. Photochemistry and Photobiology, Switzerland, v.
88, n. 3, p. 499–511, maio 2012. DOI: 10.1111/j.1751-1097.2012.01087.x.
292. COSTA, L.; COSTA, J.; TOMÉ, A. Porphyrin Macrocycle Modification: Pyrrole RingContracted or -Expanded Porphyrinoids. Molecules, Switzerland v. 21, n. 3, p. 320–320,
2016.
293. TASSO, T. T. et al. Isomeric effect on the properties of tetraplatinated porphyrins showing
optimized phototoxicity for photodynamic therapy. Dalton Transactions, United
Kingdom, v. 46, n. 33, p. 11037–11045, 2017. DOI:10.1039/C7DT01205E.
294. COCCA, L. H. Z. et al. Investigation of excited singlet state absorption and intersystem
crossing mechanism of isomeric meso-tetra(pyridyl)porphyrins containing peripheral
polypyridyl platinum(II) complexes. Chemical Physics Letters, Netherlands, v. 708, p. 1–
10, 16 set. 2018.
86
295. SOARES LOPES, L. Q. et al. Antimicrobial activity and safety applications of mesotetra(4-pyridyl)platinum(II) porphyrin. Microbial Pathogenesis, United States, v. 128, p.
47–54, mar. 2019. DOI: https://doi.org/10.1016/j.micpath.2018.12.038.
296. AFKHAMI, F.; AKBARI, S.; CHINIFORUSH, N. Entrococcus faecalis Elimination in
Root Canals Using Silver Nanoparticles, Photodynamic Therapy, Diode Laser, or Laseractivated Nanoparticles: An In Vitro Study. Journal of Endodontics, United States, v. 43,
n. 2, p. 279–282, fev. 2017. DOI: 10.1016/j.joen.2016.08.029.
297. ANNUNZIO, S. R. de et al. Susceptibility of Enterococcus faecalis and Propionibacterium
acnes to antimicrobial photodynamic therapy. Journal of Photochemistry and
Photobiology B: Biology, Netherlands, v. 178, p. 545–550, jan. 2018. DOI:
10.1016/j.jphotobiol.2017.11.035.
298. FOSCHI, F. et al. Photodynamic inactivation of Enterococcus faecalis in dental root canals
in vitro. Lasers in Surgery and Medicine, United States, v. 39, n. 10, p. 782–787, dez.
2007.
299. CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow
aerobically: approved standard. CLSI document M07-A9. Wayne, PA: Clinical And
Laboratory Standards Institute, 2012.
300. KALIL, M. A. et al. Brazilian Green Propolis as a Therapeutic Agent for the Post-surgical
Treatment of Caseous Lymphadenitis in Sheep. Frontiers in Veterinary Science,
Switzerland, v. 6, 26 nov. 2019.
301. OLIVEIRA, A. C. de et al. Polyphenolic tannin-based polyelectrolyte multilayers on
poly(vinyl chloride) for biocompatible and antiadhesive coatings with antimicrobial
properties. Progress in Organic Coatings, Netherlands, v. 194, p. 108629–108629, 20 jun.
2024. DOI: https://doi.org/10.1016/j.porgcoat.2024.108629
302. COGGAN, J. A. et al. Microbiological and histopathological aspects of canine pyometra.
Brazilian Journal of Microbiology, Rio de Janeiro, v. 39, n. 3, p. 477–483, set. 2008.
DOI: https://doi.org/10.1590/S1517-83822008000300012.
303. CHANG, A.-C. et al. Emphysematous pyometra secondary to Enterococcus avium
infection in a dog. Tierärztliche Praxis Ausgabe K Kleintiere / Heimtiere, Germany, v.
44, n. 3, p. 195–199, jan. 2016.
304. MARTÍN-PLATERO, A. M. et al. Characterization and safety evaluation of enterococci
isolated from Spanish goats’ milk cheeses. International Journal of Food Microbiology,
Netherlands, v. 132, n. 1, p. 24–32, jun. 2009.
305. FIEL, R. J. et al. Interaction of DNA with a porphyrin ligand: evidence for intercalation.
Nucleic Acids Research, England, v. 6, n. 9, p. 3093–3118, 1979. DOI:
10.1093/nar/6.9.3093.
306. MUSSER, D. A.; DATTA-GUPTA, N.; FIEL, R. J. Inhibition of DNA dependent RNA
synthesis by porphyrin photosensitizers. Biochemical and Biophysical Research
Communications, United States v. 97, n. 3, p. 918–925, 1980.
307. SANTOS, I. et al. Pyrazole-pyridinium porphyrins and chlorins as powerful
photosensitizers for photoinactivation of planktonic and biofilm forms of E. coli. Dyes and
pigments, Netherlands, v. 193, p. 109557–109557, 2021.
87
308. BEIRÃO, S. et al. Photodynamic Inactivation of Bacterial and Yeast Biofilms With a
Cationic Porphyrin. Photochemistry and Photobiology, Netherlands, v. 90, n. 6, p. 1387–
1396, 22 set. 2014. DOI: 10.1111/php.12331.
309. BOARD-DAVIES, E. L. et al. Antibacterial and Antibiofilm Potency of XF Drugs, Impact
of Photodynamic Activation and Synergy With Antibiotics. Frontiers in Cellular and
Infection Microbiology, Switzerland, v. 12, jun. 2022. DOI: 10.3389/fcimb.2022.904465.
310. CHOI, S.; BRITIGAN, B. E.; NARAYANASAMY, P. Dual Inhibition of Klebsiella
pneumoniae and Pseudomonas aeruginosa Iron Metabolism Using Gallium Porphyrin and
Gallium Nitrate. ACS Infectious Diseases, United States, v. 5, n. 9, p. 1559–1569, 16 jul.
2019. DOI: 10.1021/acsinfecdis.9b00100.
311. DA SILVA CANIELLES CAPRARA, C. et al. Charge effect of water-soluble porphyrin
derivatives as a prototype to fight infections caused by Acinetobacter baumannii by aPDT
approaches. Biofouling, United Kingdom, v. 38, n. 6, p. 605–613, 25 jul. 2022.
312. BOLSHAKOVA, A. V.; KISELYOVA, O. I.; YAMINSKY, I. V. Microbial Surfaces
Investigated Using Atomic Force Microscopy. Biotechnology Progress, United States, v.
20, n. 6, p. 1615–1622, dez. 2004. DOI: 10.1021/bp049742c.
313. DUFRÊNE, Y. F. Atomic Force Microscopy in Microbiology: New Structural and
Functional Insights into the Microbial Cell Surface. mBio, United States, v. 5, n. 4, ago.
2014.
314. FONSECA, A. P.; SOUSA, J. C. Effect of antibiotic-induced morphological changes on
surface properties, motility and adhesion of nosocomial Pseudomonas aeruginosa strains
under different physiological states. Journal of Applied Microbiology, England, v. 103, n.
5, p. 1828–1837, jun. 2007.
315. UZOECHI, S. C.; ABU-LAIL, N. I. Variations in the Morphology, Mechanics and
Adhesion of Persister and Resister E. coli Cells in Response to Ampicillin: AFM Study.
Antibiotics,[s.l], v. 9, n. 5, p. 235, maio 2020.
316. KHALID, H. F. et al. Biosurfactant coated silver and iron oxide nanoparticles with
enhanced anti-biofilm and anti-adhesive properties. Journal of Hazardous Materials,
Netherlands, v. 364, p. 441–448, 15 fev. 2019. DOI: 10.1016/j.jhazmat.2018.10.049.
317. SARAVIA, S. G. G. DE et al. Anti-adhesion and antibacterial activity of silver
nanoparticles and graphene oxide-silver nanoparticle composites. Matéria, Rio de Janeiro,
v. 25, n. 2, 2020. DOI: https://doi.org/10.1590/S1517-707620200002.1071
318. CANIGLIA, G. et al. Antimicrobial effects of silver nanoparticle-microspots on the
mechanical properties of single bacteria. The Analyst, [s.l], v. 149, n. 9, p. 2637–2646, 1
jan. 2024.
319. GREEN, D. W. The bacterial cell wall as a source of antibacterial targets. Expert Opinion
on Therapeutic Targets, England, v. 6, n. 1, p. 1–20, fev. 2002.
320. LONGO, G. et al. Antibiotic-induced modifications of the stiffness of bacterial
membranes. Journal of Microbiological Methods, Netherlands, v. 93, n. 2, p. 80–84, 22
fev. 2013.
321. WILMES, M.; SAHL, H.-G. Defensin-based anti-infective strategies. International
Journal of Medical Microbiology: IJMM, Germany, v. 304, n. 1, p. 93–9, jan. 2014.
88
322. ROBERTSON, S. N. et al. Investigation of the Antimicrobial Properties of Modified
Multilayer diamond-like Carbon Coatings on 316 Stainless Steel. Surface and Coatings
Technology, Netherlands, v. 314, p. 72–78, mar. 2017. DOI:
https://doi.org/10.1016/j.surfcoat.2016.11.035
323. HAMBLIN, M. R. et al. Polycationic photosensitizer conjugates: effects of chain length
and Gram classification on the photodynamic inactivation of bacteria. Journal of
Antimicrobial Chemotherapy, England, v. 49, n. 6, p. 941–951, jun. 2002. DOI:
10.1093/jac/dkf053.
324. LOPES, M. et al. Application of benzo[a]phenoxazinium chlorides in antimicrobial
photodynamic therapy of Candida albicans biofilms. Journal of Photochemistry and
Photobiology B Biology, Netherlands, v. 141, p. 93–99, 16 set. 2014.
325. VASSENA, C. et al. Photodynamic antibacterial and antibiofilm activity of RLP068/Cl
against Staphylococcus aureus and Pseudomonas aeruginosa forming biofilms on
prosthetic material. International Journal of Antimicrobial Agents, Netherlands, v. 44,
n. 1, p. 47–55, jul. 2014. DOI: 10.1016/j.ijantimicag.2014.03.012.
326. ALGHAMDI, F.; SHAKIR, M. The Influence of Enterococcus faecalis as a Dental Root
Canal Pathogen on Endodontic Treatment: A Systematic Review. Cureus, United States, v.
12, n. 3, p. e7257, 13 mar. 2020. DOI: 10.7759/cureus.7257.
327. MUSTAFA, E. A.; HAMDOON, S. M.; SHEHAB, E. Y. Molecular detection and
identification of Enterococcus faecium isolated from dental root canals. Iraqi Journal of
Science, Iraq, v. 62, n. 5, p. 1447–1451, 30 maio 2021.
DOI: https://doi.org/10.24996/ijs.2021.62.5.7
328. NUNES, M. R. et al. Effectiveness of Photodynamic Therapy Against Enterococcus
faecalis, With and Without the Use of an Intracanal Optical Fiber: An In Vitro Study.
Photomedicine and Laser Surgery,United States, v. 29, n. 12, p. 803–808, 26 jul. 2011. | pt_BR |
